Get the Stockscreener App
0.44
0.45%
0.00
Cognition Therapeutics Inc stock is traded at $0.44, with a volume of 46,899.
It is up +0.45% in the last 24 hours and down -6.30% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$0.44
Open:
$0.44
24h Volume:
46,899
Relative Volume:
0.09
Market Cap:
$17.86M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-0.5116
EPS:
-0.86
Net Cash Flow:
$-20.87M
1W Performance:
-13.60%
1M Performance:
-6.30%
6M Performance:
-80.53%
1Y Performance:
-55.80%
1-Day Range:
$0.435
$0.4454
1-Week Range:
$0.4264
$0.51
52-Week Range:
$0.34
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2403 SIDNEY STREET, PITTSBURGH
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CGTX | 0.437 | 17.86M | 0 | -22.83M | -20.87M | -0.86 |
| VRTX | 448.66 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.56 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.27 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Life Sciences Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Cognition Therapeutics Inc Reports Q3 2024 GAAP EPS of $(0.25), Missing Estimates; Net Loss Widens to $9.9 Million - GuruFocus.com
Cognition Therapeutics Reports Promising Q3 2024 Results - TipRanks
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - Yahoo Finance
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum - The Manila Times
Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.00 - Defense World
Cognition Therapeutics stock rated Buy, target held amid CT1812 data By Investing.com - Investing.com UK
November’s Small-Cap Treasures: 3 Stocks Poised for Growth - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital - Defense World
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with - The Bakersfield Californian
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD - Yahoo Finance
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough By Investing.com - Investing.com South Africa
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough - Investing.com
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - GlobeNewswire
Cognition Therapeutics (CGTX) Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - StreetInsider.com
Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Dementia Associated With Alzheimer's Disease Pipeline - openPR
Cognition Therapeutics (NASDAQ:CGTX) versus Ocugen (NASDAQ:OCGN) Head-To-Head Survey - Defense World
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate ... - The Bakersfield Californian
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) - Yahoo Canada Finance
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies At The Horizon Expected To Transform The Treatment Paradigm, Assesses D... - MENAFN.COM
Tau Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - India Shorts
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ... By GuruFocus - Investing.com Canada
Cognition Therapeutics stock hits 52-week low at $0.4 - Investing.com
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
Cognition Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA - openPR
Cognition Therapeutics Inc (CGTX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference - ForexTV.com
Cognition Therapeutics Inc (CGTX)’s Day in Review: Closing at 0.47, Up by 11.36 - The Dwinnex
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved - The Bakersfield Californian
Cognition Therapeutics Supports Lewy Body Dementia - GlobeNewswire
Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders - TipRanks
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Decrease in Short Interest - Defense World
Cognition Therapeutics Inc (CGTX) Stock: A Year of Decreases and Increases - The InvestChronicle
Trading Day Review: Cognition Therapeutics Inc (CGTX) Loses Momentum, Closing at 0.41 - The Dwinnex
Conduit Pharmaceuticals Inc (CDT) expanding its growth trajectory ahead - SETE News
Capricor Therapeutics rockets on plan to file BLA for full approval of deramiocel - The Pharma Letter
Point72 DIFC Ltd Acquires New Holdings in The Carlyle Group Inc. (NASDAQ:CG) - Defense World
Stock Performance Spotlight: Comtech Telecommunications Corp. (CMTL) Ends the Day at 4.46, Down by -1.11 - The Dwinnex
Pacer Advisors Inc. Boosts Stake in Cognizant Technology Solutions Co. (NASDAQ:CTSH) - Defense World
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):